The U.S. Food and Drug Administration (FDA) granted approval for revised commercial labeling of Medtronic’s Intellis™ Platform with Differential Target Multiplexed (DTM™). The platform is meant to treat chronic and intractable leg and back pain. Charlie Covert, VP and GM of Pain Therapies within the Neuromodulation business, part of the Neuroscience Portfolio at Medtronic, stated, “The body of clinical evidence proving the efficacy of DTM SCS in treating patients with chronic back pain continues to grow. The updated labeling further strengthens the credibility of the outcomes from this therapy, and parallels the profound benefits our clinician partners are seeing with their own patients.”
Read more here.
More on: News Regulatory